EU/3/20/2293: Orphan designation for the treatment of Becker muscular dystrophy
Table of contents
On 26 June 2020, orphan designation EU/3/20/2293 was granted by the European Commission to MWB Consulting S.A.R.L., France, for (+)-epicatechin for the treatment of Becker muscular dystrophy.
Treatment of Becker muscular dystrophy
|Orphan designation status||
|EU designation number||
|Date of designation||
MWB Consulting S.A.R.L.
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: